Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Assets Average (2016 - 2025)

Historic Assets Average for Spyre Therapeutics (SYRE) over the last 10 years, with Q3 2025 value amounting to $521.7 million.

  • Spyre Therapeutics' Assets Average rose 2173.23% to $521.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $521.7 million, marking a year-over-year increase of 2173.23%. This contributed to the annual value of $475.2 million for FY2024, which is 13010.56% up from last year.
  • Spyre Therapeutics' Assets Average amounted to $521.7 million in Q3 2025, which was up 2173.23% from $554.3 million recorded in Q2 2025.
  • Spyre Therapeutics' 5-year Assets Average high stood at $589.1 million for Q1 2025, and its period low was $61.8 million during Q1 2023.
  • In the last 5 years, Spyre Therapeutics' Assets Average had a median value of $162.6 million in 2021 and averaged $270.6 million.
  • Per our database at Business Quant, Spyre Therapeutics' Assets Average plummeted by 4062.82% in 2022 and then soared by 57110.12% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Assets Average (Quarter) stood at $119.5 million in 2021, then tumbled by 31.92% to $81.4 million in 2022, then soared by 237.49% to $274.6 million in 2023, then surged by 87.49% to $514.8 million in 2024, then grew by 1.35% to $521.7 million in 2025.
  • Its Assets Average stands at $521.7 million for Q3 2025, versus $554.3 million for Q2 2025 and $589.1 million for Q1 2025.